Sartorius Stedim Biotech stock gets fresh analyst targets

Published on 10/04/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim Biotech stock drew a EUR 281.00 target from Oddo BHF on October 2, 2026. H1 revenue reached EUR 1.527 billion and EBITDA EUR 463.7 million.

Flatlay mit Laborpipetten, Filtermembranen, Schutzhandschuhen und ISIN-Karte FR0013154002 — Sartorius Stedim Biotech Flatlay mit Laborpipetten, Filtermembranen, Aktien-Zertifikat und ISIN-Karte, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech stock was last at EUR 208.20 on Euronext Paris on October 2, 2026, after Oddo BHF raised its price target to EUR 281.00. The upgrade puts analyst expectations above the current quotation, while the companys first-half figures provide the operating backdrop.

Oddo BHF lifts its target

According to Ideal Investisseur on October 2, 2026, Oddo BHF increased its target from EUR 239.00 to EUR 281.00 and retained an Outperform rating. The same report said Goldman Sachs had raised its target from EUR 208.00 to EUR 223.00 on October 1, 2026, alongside a Buy rating.

Goldman Sachs separately maintained its Buy rating and EUR 223.00 target, according to Markets Insider on October 1, 2026. The report also cited a Strong Buy consensus with an average target of EUR 238.83.

First-half figures set the test

Sartorius Stedim Biotech reported first-half 2026 revenue of EUR 1.527 billion, EBITDA of EUR 463.7 million and an EBITDA margin of 31.4 percent. Net income reached EUR 181.1 million for the period, according to Ideal Investisseur.

The companys 2026 guidance calls for revenue of EUR 3.154 billion and EBITDA of EUR 989.2 million, with constant-currency revenue growth of 6 to 10 percent. The investor-relations page describes consumables as the main growth driver while equipment is expected to remain at least stable, linking the target debate to the pace of customer investment recovery.

Consensus stays above the quotation

StockAnalysis lists a Buy consensus from 14 analysts and an average price target of EUR 237.29. That target is 13.97 percent above the EUR 208.20 reference price, a gap that quantifies the optimism already embedded in current coverage.

The next confirmed earnings date is October 22, 2026, according to StockAnalysis. For investors, the next results will show whether the first-half margin and the full-year guidance can support the elevated analyst targets.

Stock holds above EUR 200

Sartorius Stedim Biotech was last at EUR 208.20 on Euronext Paris on October 2, 2026 at 5:35 p.m. CET. The session range was EUR 204.20 to EUR 211.20, while the 52-week range stood at EUR 150.00 to EUR 224.00.